Addressing drug shortages and enhancing domestic production of critical medicines Issues and proposed legislation related to long-term sustainability of access for patients to generic and biosimilar medicines, including but not limited to pharmaceutical supply chain security, drug shortages, biosimilar interchangeability, and PBM reform Issues related to Medicaid Generics Penalty Issues related to possible drug shortage of levothyroxine capsules Issues related to tariffs Appropriations for increasing domestic manufacturing of generic medicines
2025 · 1st Quarter (Jan 1 - Mar 31)
AMNEAL PHARMACEUTICALS
Filed by AMNEAL PHARMACEUTICALS.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- Not reported
- Expenses
- $910,000.00
- Registrant
- AMNEAL PHARMACEUTICALS
- Client
- AMNEAL PHARMACEUTICALS
- Filing UUID
- 40ef23d1-0427-4305-80d6-d68a4f681017
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.